Intensity Therapeutics, Inc. Common stock earnings per share and revenue
On Nov 06, 2025, INTS reported earnings of -0.06 USD per share (EPS) for Q3 25, beating the estimate of -0.08 USD, resulting in a 32.81% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -6.22% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
What were Intensity Therapeutics, Inc. Common stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Intensity Therapeutics, Inc. Common stock reported EPS of -$0.06, beating estimates by 32.81%, and revenue of $0.00, 0% as expectations.
How did the market react to Intensity Therapeutics, Inc. Common stock's Q3 2025 earnings?
The stock price moved down -6.22%, changed from $0.49 before the earnings release to $0.46 the day after.
When is Intensity Therapeutics, Inc. Common stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Intensity Therapeutics, Inc. Common stock's next earnings report?
Based on --
analysts, Intensity Therapeutics, Inc. Common stock is expected to report EPS of -- and revenue of -- for Q-- --.